ALS has very few therapeutic options in terms of drugs other than riluzole which may prolong survival by ~10%, although the antisense oligonucleotides Tofersen and ION363/Jacifusen have been able to reverse the phenotype in a few patients with aggressive mutations of Cu/Zn superoxide-dismutase1 (SOD1) and fused in sarcoma RNA-binding protein (FUS) [3,4,5]. This evidence concerns the gene FUS and amyotrophic lateral sclerosis.